Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: A 3-year follow-up

Ophthalmologica

Volumn 229, Issue 3, 2013, Pages 158-167

  Marques, Inês P ^a,b   Fonseca, Pedro ^a,b,c   Luz Cachulo, M ^a,b   Pires, Isabel ^a,b   Figueira, João ^a,b,c   Faria De Abreu, J R ^b   Silva, Rufino ^a,b,c  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Age related macular degeneration; Antiangiogenesis agents; Choroidal neovascularization; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; EXUDATIVE MACULAR DEGENERATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PREDICTIVE VALUE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL IMPAIRMENT; AGE RELATED MACULAR DEGENERATION; BEST CORRECTED VISUAL ACUITY; BIOMICROSCOPY; EYE; STEREOSCOPIC MACULAR BIOMICROSCOPY; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84876490799     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000343709     Document Type: Article

References (19)

1. Bressler NM: Age related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900-1901. (Pubitemid 38509505)
2. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age related mac-u lar degeneration. New Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
3. Brown DM, Michels M, Kaiser PK, et al: Ranibizumab versus verteporfin photodynam-ic therapy for neovascular age-related macu-lar degeneration. New Engl J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
4. Brown DM, Michels M, Kaiser PK, et al: Ranibizumab versus verteporfin photodynam-ic therapy for neovascular age-related macu-lar degeneration: two year results of ANCHOR study. Ophthalmology 2009; 116: 57-65.
5. Gupta P, Shienbaum G, et al: A treat and extend regimen using ranibizumab for neovas-cular age-related macular degeneration: clinical and economic impact. Ophthalmology 2010; 117:2134-2140.
6. Cohen SY, Dubois L, Tadayoni R, et al: Results of one year's treatment with ranibizum-ab for age-related macular degeneration in a clinical setting, Am J Ophthalmol 2009; 148: 409-413.
7. Rothenbuehler SP, Waeber D, Brinkman CK, et al: Effects of ranibizumab in patients with subfoveal choroidal neovasculariza-tion attributable to age-related macular degeneration. Am J Ophthalmol 2009: 147: 831-837
8. Querques G, Azrya S, Martinelli D, et al: Ranibizumab for exsudative age-related macu-lar degeneration: 24 month outcomes from a single-center institutional setting. Br J Ophthalmol 2010; 94: 292-296.
9. Dadgostar H, Ventura AA, Chung JY, et al: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monother-apy in exudative age-related macular degeneration. Opht halmology 2009; 116: 1740-1747.
10. Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Opht ha lmol 2007; 144: 627-637.
11. Abedi G, Patal P, Doros G, Subramanian ML: Transitioning from Stratus OCT to Cirrus OCT: a comparison and a proposed equation to convert central subfield macular thickness measurements in healthy subjects. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1353-1357.
12. Regillo CD, Brown DM, Abraham P, et al: Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
13. Bolz M, Schmidt-Erfurth U; Ranibizumab EXCITE study: exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macu-lar degeneration. 8th EURETINA Congress, Vienna, May 22-25, 2008
14. Eyeworld.org: Lucentis at one year. http://www.eyeworld.org/printarticle. php?id =4390 (accessed November 21, 2008).
15. Meyer CH, Eter N, Holz FG, et al: Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial. Invest Ophthalmol Vis Sci 2008; 49:E-abstract 273.
16. Fung AE, Lalwani GA, Rosenfeld PJ, et al: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibi-zumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
17. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, et al: A variable-dosing regimen with in-travitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthal mol 2009; 148: 43-58.
18. The CATT Research Group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-1908
19. Horizonsupportive clinical evidence. http://www.lucentis.com/hcp/amd/ horizon. html.